AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
The Pharma Data
APRIL 28, 2021
1 The safety profile of SKYRIZI in these studies was generally consistent with the safety profile of SKYRIZI in plaque psoriasis, with no new safety risks observed. 3 percent; Patient’s Assessment of Pain Numerical Rating Scale (NRS) ?1.5; Patient Global Assessment-Disease Activity NRS ?2.0; HAQ-DI score ?0.5;
Let's personalize your content